Mexico City, Mexico.- Cuban diagnostic technology SUMA has been used in Mexico for more than 20 years with effective results, stated María Elena Selles León, general manager of Tecnosuma México S.A.
Speaking to Prensa Latina, León, who holds a degree in Microbiology from the University of Havana, explained that in 2006 the Immunoassay Center completed an agreement with the Mexican company Ensayos y Tamizajes de S.A. for the joint production of SUMA. For more than 10 years, she pointed out, the Mexican Institute of Social Security (IMSS) and other public and private hospitals have used reagents from this useful technology manufactured in Mexico, with positive results in health rates.
In Mexico SUMA is used in the screening program for the early diagnosis of hereditary metabolic diseases TamizNeonatal, such as congenital hypothyroidism, adrenal hyperplasia, galactosemia, phenylketonuria and biotinidase deficiency, explains.
The SUMA Technology (UltraMicroanalytical System) is an advanced technique in the diagnosis of congenital metabolic diseases, developed in the Immunoassay Center of Havana.
SUMA is characterized by small volumes of samples to be processed, either blood, plasma and other bodily fluids, and savings in reagents. Their experts are on a par with the most developed, with reliable and timely diagnoses that avoid repetitions and the occurrence of false positives or negatives.
It is a widely recognized brand whose results are supported by prestigious external quality control programs such as those applied by the Centers for Disease Control of Atlanta, or the Buenos Aires Foundation, which attest to the excellence of their products.
Thanks to the Suma Technology, Cuba was the second country in America to have a complete diagnostic and attention program for Congenital Hypothyroidism.